18147 results
-
List item
Human medicine European public assessment report (EPAR): Libtayo (updated)
Cemiplimab, Carcinoma, Squamous Cell
Date of authorisation: 28/06/2019,
, 
, Revision: 6, Authorised, Last updated: 07/04/2021
-
List item
Human medicine European public assessment report (EPAR): Senshio (updated)
ospemifene, Postmenopause
Date of authorisation: 14/01/2015,, Revision: 11, Authorised, Last updated: 07/04/2021
-
List item
Human medicine European public assessment report (EPAR): Vaxchora (updated)
vibrio cholerae, strain cvd 103-hgr, live, Cholera
Date of authorisation: 01/04/2020,, Revision: 2, Authorised, Last updated: 07/04/2021
-
List item
Human medicine European public assessment report (EPAR): Cimzia (updated)
Certolizumab pegol, Arthritis, Rheumatoid
Date of authorisation: 01/10/2009, Revision: 30, Authorised, Last updated: 07/04/2021 -
List item
Human medicine European public assessment report (EPAR): Competact (updated)
pioglitazone, metformin hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 28/07/2006, Revision: 19, Authorised, Last updated: 07/04/2021 -
List item
Human medicine European public assessment report (EPAR): Bemrist Breezhaler (updated)
indacaterol, Mometasone furoate, Asthma
Date of authorisation: 30/05/2020, Revision: 1, Authorised, Last updated: 07/04/2021 -
List item
Human medicine European public assessment report (EPAR): Kisplyx (updated)
lenvatinib mesilate, Carcinoma, Renal Cell
Date of authorisation: 25/08/2016,, 
, Revision: 13, Authorised, Last updated: 07/04/2021
-
List item
Human medicine European public assessment report (EPAR): Tysabri (updated)
natalizumab, Multiple Sclerosis
Date of authorisation: 27/06/2006, Revision: 33, Authorised, Last updated: 06/04/2021 -
List item
Human medicine European public assessment report (EPAR): Inbrija (updated)
levodopa, Parkinson Disease
Date of authorisation: 19/09/2019, Revision: 2, Authorised, Last updated: 06/04/2021 -
List item
Human medicine European public assessment report (EPAR): Pemetrexed Hospira (updated)
pemetrexed, Carcinoma, Non-Small-Cell Lung, Mesothelioma
Date of authorisation: 19/11/2015,
, Revision: 11, Authorised, Last updated: 06/04/2021
-
List item
Veterinary medicine European public assessment report (EPAR): Letifend (updated)
Recombinant protein Q from Leishmania infantum MON-1, Dogs
Date of authorisation: 20/04/2016, Revision: 9, Authorised, Last updated: 06/04/2021 -
List item
Human medicine European public assessment report (EPAR): Exviera (updated)
dasabuvir sodium, Hepatitis C, Chronic
Date of authorisation: 14/01/2015,, , Revision: 19, Authorised, Last updated: 06/04/2021
-
List item
Human medicine European public assessment report (EPAR): Cresemba (updated)
isavuconazole, Aspergillosis
Date of authorisation: 15/10/2015,
, Revision: 10, Authorised, Last updated: 06/04/2021
-
List item
Human medicine European public assessment report (EPAR): Aybintio (updated)
bevacizumab, Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms
Date of authorisation: 19/08/2020,, 
, Revision: 2, Authorised, Last updated: 06/04/2021
-
List item
Human medicine European public assessment report (EPAR): Truvada (updated)
emtricitabine, tenofovir disoproxil fumarate, HIV Infections
Date of authorisation: 20/02/2005, Revision: 44, Authorised, Last updated: 31/03/2021 -
List item
Human medicine European public assessment report (EPAR): Incresync (updated)
alogliptin, pioglitazone, Diabetes Mellitus, Type 2
Date of authorisation: 19/09/2013, Revision: 9, Authorised, Last updated: 31/03/2021 -
List item
Human medicine European public assessment report (EPAR): Vipidia (updated)
alogliptin, Diabetes Mellitus, Type 2
Date of authorisation: 18/09/2013, Revision: 5, Authorised, Last updated: 31/03/2021 -
List item
Human medicine European public assessment report (EPAR): Ivozall (updated)
clofarabine, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 14/11/2019,, Revision: 2, Authorised, Last updated: 31/03/2021
-
List item
Human medicine European public assessment report (EPAR): Fycompa (updated)
perampanel, Epilepsies, Partial
Date of authorisation: 23/07/2012, Revision: 20, Authorised, Last updated: 31/03/2021 -
List item
Human medicine European public assessment report (EPAR): Keytruda (updated)
Pembrolizumab, Melanoma, Hodgkin Disease, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Urologic Neoplasms, Squamous Cell Carcinoma of Head and Neck
Date of authorisation: 17/07/2015,, Revision: 32, Authorised, Last updated: 31/03/2021
-
List item
Human medicine European public assessment report (EPAR): Alli (previously Orlistat GSK) (updated)
orlistat, Obesity
Date of authorisation: 22/07/2007, Revision: 17, Authorised, Last updated: 31/03/2021 -
List item
Human medicine European public assessment report (EPAR): Repatha (updated)
Evolocumab, Dyslipidemias, Hypercholesterolemia
Date of authorisation: 17/07/2015, Revision: 17, Authorised, Last updated: 31/03/2021 -
List item
Human medicine European public assessment report (EPAR): Levetiracetam Teva (updated)
levetiracetam, Epilepsy
Date of authorisation: 25/08/2011,, Revision: 17, Authorised, Last updated: 31/03/2021
-
List item
Human medicine European public assessment report (EPAR): Amyvid (updated)
florbetapir (18F), Radionuclide Imaging
Date of authorisation: 14/01/2013, Revision: 14, Authorised, Last updated: 31/03/2021 -
List item
Human medicine European public assessment report (EPAR): Matever (updated)
levetiracetam, Epilepsy
Date of authorisation: 03/10/2011,, Revision: 22, Authorised, Last updated: 31/03/2021